Viridian Therapeutics, Inc./DE Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Viridian Therapeutics, Inc./DE (VRDN) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $20.51 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-02-26
- Viridian Therapeutics, Inc./DE share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2016-03-31 was $2.76, a 50.71% decline year-over-year.
- Viridian Therapeutics, Inc./DE share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2015-03-31 was $5.60.
- Viridian Therapeutics, Inc./DE share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $20.51.
- Viridian Therapeutics, Inc./DE share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2016 was $38.83, a 1714.49% increase from fiscal 2015.
- Viridian Therapeutics, Inc./DE share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2015 was $2.14, a 60.59% decline from fiscal 2014.
- Viridian Therapeutics, Inc./DE share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2014 was $5.43.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2025-12-31 | $20.51 10-K · filed 2026-02-26 | |||
| 2016-12-31 | $38.83 10-K · filed 2017-03-24 | |||
| 2016-09-30 | $2.64 10-Q · filed 2016-10-26 | |||
| 2016-06-30 | $2.92 10-Q · filed 2016-08-15 | |||
| 2016-03-31 | $2.76 10-Q · filed 2016-05-16 | |||
| 2015-12-31 | $2.14 10-K · filed 2016-03-21 | |||
| 2015-09-30 | $3.45 10-Q · filed 2015-11-13 | |||
| 2015-06-30 | $3.37 10-Q · filed 2015-08-14 | |||
| 2015-03-31 | $5.60 10-Q · filed 2015-05-15 | |||
| 2014-12-31 | $5.43 10-K · filed 2015-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |